Do you have patients who would benefit from non-branded Lilly insulins?

Consider Lilly's portfolio of non-branded insulins for patients who face high out-of-pocket costs* for their Humalog-branded insulin.

phone

Call The Lilly Answers Center
Call: 1-800-LillyRx (1-800-545-5979)

Patient Image
Patient Image

Do you have patients who would benefit from non-branded Lilly insulins?

Consider Lilly's portfolio of non-branded insulins for patients who face high out-of-pocket costs* for their Humalog-branded insulin.

*Note that for many people with commercial drug insurance, Lilly's branded insulins may still have a lower out-of-pocket cost than Lilly's lower list-priced insulins.

Out-of-pocket costs may vary depending on a patient’s plan. Please contact plan administrator for most current information.

Humalog (insulin lispro injection, 100 units/mL) and Insulin Lispro Injection (100 units/mL) are indicated to improve glycemic control in adults and children with diabetes mellitus. Humalog Mix75/25 (insulin lispro protamine and insulin lispro injectable suspension, 100 units/mL) and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 (100 units/mL) are indicated to improve glycemic control in patients with diabetes mellitus.

Limitations of Use: The proportions of rapid-acting and intermediate-acting insulins in Humalog Mix75/25, and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 are fixed and do not allow for basal versus prandial dose adjustments.

These non-branded insulin lispro products feature the same molecule as the Humalog-branded insulin products you are familiar with.

  • Same safety and efficacy profile
  • Same manufacturer
  • Same KwikPen® and vial

Continue to write the Humalog-branded product.

Pharmacists can determine the most affordable Lilly insulin option for your patients.

Humalog, Insulin Lispro Injection, Humalog Mix75/25, and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 are contraindicated during episodes of hypoglycemia and in patients who are hypersensitive to these insulins or any of their excipients.

All of Lilly's non-branded insulins are available in a Kwikpen, which is a small lightweight, prefilled insulin pen for patients with diabetes who want a portable device.

For proper administration, pharmacists should engage patients and caregivers to discuss the Instructions for Use for these insulins.

Note that for many people with commercial drug insurance, Lilly's branded insulins may still have a lower out-of-pocket cost than Lilly's lower list-priced insulins. Pharmacists, please see the information below about “Steps to ensure Humalog patients get the most affordable Lilly insulin option.”

Vials are available only for Lilly’s Insulin Lispro Injection U-100.
¶Out-of-pocket costs may vary depending on a patient’s plan. Please contact plan administrator for most current information.

Vial and Pen
Branded Name Non-branded Name
Humalog® U-100 Insulin Lispro Injection U-100
Humalog® Mix75/25™ Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 KwikPen
Humalog® Junior KwikPen® Insulin Lispro Injection Junior KwikPen

How to stock and order

Sales Package Information and Specifications

Sales Package Size NDC and UPC Wholesale Acquisition Cost (WAC)*
INSULIN LISPRO INJECTION
KWIKPEN 100 U/ML
3 ML X 5
NDC: 66733-822-59 & 0002-8222-59
UPC: 3-66733-822-59-4
$265.20
INSULIN LISPRO INJECTION
100 U/ML
10 ML X 1 VIAL
NDC: 66733-773-01 & 0002-7737-01
UPC: 3-66733-773-01-8
$137.35
INSULIN LISPRO PROTAMINE
AND INSULIN LISPRO
INJECTABLE SUSPENSION
MIX75/25 KWIKPEN
NDC: 0002-8233-05
UPC: 3-00028-233-05-4
$265.20
INSULIN LISPRO INJECTION
JUNIOR KWIKPEN 100 U/ML
3 ML X 5
NDC: 0002-7752-05
UPC: 3-0002-7752-05-1
$265.20
*The Lilly WAC is the listed price to the distribution channel not including prompt pay, service or administrative fees, stocking or distribution allowances, or any discounts, rebates, or chargebacks provided by Lilly USA, LLC to any entity.
Product Carton
Dimensions
(L x W x H)
(inches)
Carton
Weight
(ounces)
Cartons
Per Case
Case
Dimensions
(L x W x H)
(inches)
Case
Weight
(pounds)
Case
Per Pallet
INSULIN LISPRO INJECTION
KWIKPEN 100 U/ML
3 ML X 5
3.6 x 1.1 x 5.8 6.72 36 15.1 x 11.1 x 6.6 16.24 77
INSULIN LISPRO INJECTION
100 U/ML
10 ML X 1 VIAL
1.8 x 1.5 x 2.6 1.25 100 18.8 x 8.2 x 5.9 8.5 70
INSULIN LISPRO PROTAMINE
AND INSULIN LISPRO INJECTABLE
SUSPENSION MIX75/25™ KWIKPEN
3.6 x 1.1 x 5.8 6.72 36 15.1 x 11.1 x 6.6 16.24 77
INSULIN LISPRO INJECTION
JUNIOR KWIKPEN 100 U/ML
3 ML X 5
3.6 x 1.1 x 5.8 6.6 36 15.1 x 11.1 x 6.6 16.24 77

How to stock and order Lilly's Insulin Lispro Injection

Sales Package Information and Specifications

Sales Package
Size
NDC and UPC Wholesale
Acquisition
Cost (WAC)*
INSULIN LISPRO
INJECTION
KWIKPEN 100 U/ML
3 ML X 5
NDC: 66733-822-59 0002-8222-59
UPC: 3-66733-822-59-4
$265.20
INSULIN LISPRO
INJECTION
100 U/ML
10 ML X 1 VIAL
NDC: 66733-773-01 0002-7737-01
UPC: 3-66733-773-01-8
137.35
INSULIN LISPRO
PROTAMINE AND
INSULIN LISPRO
INJECTABLE
SUSPENSION
MIX75/25 KWIKPEN
NDC: 0002-8233-05
UPC: 3-00028-233-05-4
265.20
INSULIN LISPRO
INJECTION JUNIOR
KWIKPEN 100 U/ML
3 ML X 5
NDC: 0002-7752-05
UPC: 3-0002-7752-05-1
265.20
*The Lilly WAC is the listed price to the distribution channel not including prompt pay, service or administrative fees, stocking or distribution allowances, or any discounts, rebates, or chargebacks provided by Lilly USA, LLC to any entity.
Product Carton
Dimensions
(L x W x H)
(inches)
Carton
Weight
(ounces)
Cartons
Per Case
INSULIN LISPRO
INJECTION
KWIKPEN 100 U/ML
3 ML X 5
3.6 x 1.1 x 5.8 6.72 36
INSULIN LISPRO
INJECTION
100 U/ML
10 ML X 1 VIAL
1.8 x 1.5 x 2.6 1.25 100
INSULIN LISPRO
PROTAMINE AND
INSULIN LISPRO
INJECTABLE
SUSPENSION
MIX75/25™ KWIKPEN
3.6 x 1.1 x 5.8 6.72 36
INSULIN LISPRO
INJECTION JUNIOR
KWIKPEN 100 U/ML
3 ML X 5
3.6 x 1.1 x 5.8 6.6 36
Product Carton
Dimensions
(L x W x H)
(inches)
Carton
Weight
(ounces)
Cartons
Per Case
INSULIN LISPRO
INJECTION
KWIKPEN 100 U/ML
3 ML X 5
15.1 x 11.1 x 6.6 16.24 77
INSULIN LISPRO
INJECTION
100 U/ML
10 ML X 1 VIAL
18.8 x 8.2 x 5.9 8.5 70
INSULIN LISPRO
PROTAMINE AND
INSULIN LISPRO
INJECTABLE
SUSPENSION
MIX75/25™ KWIKPEN
15.1 x 11.1 x 6.6 16.24 77
INSULIN LISPRO
INJECTION JUNIOR
KWIKPEN 100 U/ML
3 ML X 5
15.1 x 11.1 x 6.6 16.24 77

Minimum Order Quantity: 1 carton of 5 KwikPens or 100 vials
Billing Quantity: 15 mL per 5-pen pack or 10 mL per vial
Prescription Legend: Yes
Returned Goods: Please visit www.lillytrade.com for further details.
Distribution: Lilly USA Authorized Distributors of Record
Storage: Refrigeration is required during storage and handling (36°F to 46°F [2°C to 8°C]). Patients may store Insulin Lispro Injection at room temperature (below 86°F [30°C]) up to 28 days. Patients may store Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 at room temperature (Below 86°F [30°C]) up to 10 days. For any questions regarding storage and handling, call 1-800-LillyRx (1-800-545-5979).
TAA Compliant: Yes
Country of Origin: USA

Steps to ensure Humalog patients get the most affordable Lilly insulin option:

How to compare out-of-pocket cost (KwikPen example):

  1. Take two substitutable medicines (example: Humalog and Insulin Lispro Injection).
  2. Run the NDC for each – Humalog U-100 KwikPen 0002-8799-59 and Lilly’s Insulin Lispro Injection KwikPen 66733-822-59.
  3. Dispense the Lilly insulin that offers your patient the lower out-of-pocket cost and inform them if a substitution was made.

The Lilly Diabetes Solution Center may be able to help patients who need additional assistance paying for medications or care. Encourage your patients to call the Lilly Diabetes Solution Center at 1-833-808-1234.

Indications and Important Safety Information for Humalog Brand of Insulins and Lilly’s Insulin Lispro Injectable Products

Humalog and Insulin Lispro Injection are indicated to improve glycemic control in adults and children with diabetes mellitus.  Humalog Mix75/25, Humalog Mix50/50, and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 are mixtures of intermediate-acting and rapid-acting insulin analogs indicated to improve glycemic control in patients with diabetes mellitus.

Limitations of Use: The proportions of rapid-acting and intermediate-acting insulins in Humalog Mix75/25, Humalog Mix50/50, and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 are fixed and do not allow for basal versus prandial dose adjustments.

Important Safety Information for Humalog Brand of Insulins and Lilly's Insulin Lispro Injectable Products

  • Contraindications

Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50 are contraindicated during episodes of hypoglycemia and in patients who are hypersensitive to these insulins or any of their excipients.

  • Warnings and Precautions

Never share a Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, or Humalog Mix50/50 prefilled pen, cartridge, reusable pen compatible with Lilly 3 mL cartridges, or syringe between patients, even if the needle is changed. Patients using vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.

Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in insulin strength, manufacturer, type, injection site, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Any changes in insulin regimen should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. Due to reports of hyperglycemia and hypoglycemia, advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor blood glucose. For patients with type 2 diabetes, dosage adjustments of concomitant antidiabetic products may be needed.

Hypoglycemia: Severe hypoglycemia may be life threatening and can cause seizures or death. Hypoglycemia is the most common adverse reaction of Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50. Monitor blood glucose and increase monitoring frequency with changes to insulin dosage, use with glucose-lowering medications, meal pattern, physical activity; in patients with renal or hepatic impairment; and in patients with hypoglycemia unawareness.

Hypoglycemia Due to Medication Errors: Instruct patients to always check the insulin label before each injection to avoid medication errors. Humalog U-200 should not be transferred from the Humalog KwikPen to a syringe as overdose and severe hypoglycemia can occur.

Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50. If hypersensitivity reactions occur, discontinue the use of insulin and treat per standard of care until signs and symptoms resolve.

Hypokalemia: Hypokalemia may be life threatening. Insulins, including Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50, cause a shift in potassium from the extracellular to intracellular space possibly leading to hypokalemia, which, if untreated, may result in respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia (e.g., patients using potassium-lowering medications or medications sensitive to serum potassium concentrations).

Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists: Thiazolidinediones (TZDs), which are PPAR-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin, including Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50. This may lead to or exacerbate heart failure. Observe patients for signs and symptoms of heart failure and consider discontinuation or dose reduction of the PPAR-gamma agonist.

Hyperglycemia and Ketoacidosis Due to Insulin Pump Device Malfunction: Malfunction of the insulin pump device, infusion set, or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Patients using subcutaneous insulin infusion pumps must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure.

  • Adverse Reactions

Adverse reactions associated with Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50 include hypoglycemia, hypokalemia, allergic reactions, injection-site reactions, lipodystrophy, pruritus, rash, weight gain, and peripheral edema.

  • Drug Interactions

Some medications may alter glucose metabolism, insulin requirements, and the risk for hypoglycemia or hyperglycemia. Signs of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs. Particularly close monitoring may be required.

Please click to access Humalog  Full Prescribing Information, Humalog U-100  Patient Prescribing Information, Humalog U-200  Patient Prescribing Information, Humalog Mix75/25  Full Prescribing Information, Humalog Mix75/25  Patient Prescribing Information, Humalog Mix50/50  Full Prescribing Information, Humalog Mix50/50  Patient Prescribing Information, Insulin Lispro Injection Full Prescribing Information, and Insulin Lispro Injection  Patient Prescribing Information, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 Full Prescribing Information, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 Patient Prescribing Information, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 KwikPen Instructions for Use, Insulin Lispro Injection Junior KwikPen Instructions for Use.

Please click to access  Humalog U-100 KwikPen Instructions for Use, Humalog Junior KwikPen Instructions for Use, Humalog U-100 Vial Instructions for Use, Humalog Mix75/25 KwikPen Instructions for Use, Insulin Lispro Injection KwikPen Instructions for Use, and Insulin Lispro Injection Vial Instructions for Use included with your medication.

HI BOI SP U100 75/25 HCP ISI 10JAN2020

Humalog®, KwikPen®, Humalog® Junior KwikPen®, Humalog® Mix75/25TM, and Humalog® Mix50/50TM are trademarks and registered trademarks of Eli Lilly and Company, its subsidiaries, or affiliates, and are available by prescription only. 

Reference: 1. Data on file. Lilly USA, LLC; KwikPen Design Validation User Study. HUM20071024A.

Indications and Important Safety Information for Humalog Brand of Insulins and Lilly’s Insulin Lispro Injectable Products

Read More

Humalog and Insulin Lispro Injection are indicated to improve glycemic control in adults and children with diabetes mellitus.  Humalog Mix75/25, Humalog Mix50/50, and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 are mixtures of intermediate-acting and rapid-acting insulin analogs indicated to improve glycemic control in patients with diabetes mellitus.

Limitations of Use: The proportions of rapid-acting and intermediate-acting insulins in Humalog Mix75/25, Humalog Mix50/50, and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 are fixed and do not allow for basal versus prandial dose adjustments.

Important Safety Information for Humalog Brand of Insulins and Lilly's Insulin Lispro Injectable Products

  • Contraindications

Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50 are contraindicated during episodes of hypoglycemia and in patients who are hypersensitive to these insulins or any of their excipients.

  • Warnings and Precautions

Never share a Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, or Humalog Mix50/50 prefilled pen, cartridge, reusable pen compatible with Lilly 3 mL cartridges, or syringe between patients, even if the needle is changed. Patients using vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.

Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in insulin strength, manufacturer, type, injection site, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Any changes in insulin regimen should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. Due to reports of hyperglycemia and hypoglycemia, advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor blood glucose. For patients with type 2 diabetes, dosage adjustments of concomitant antidiabetic products may be needed.

Hypoglycemia: Severe hypoglycemia may be life threatening and can cause seizures or death. Hypoglycemia is the most common adverse reaction of Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50. Monitor blood glucose and increase monitoring frequency with changes to insulin dosage, use with glucose-lowering medications, meal pattern, physical activity; in patients with renal or hepatic impairment; and in patients with hypoglycemia unawareness.

Hypoglycemia Due to Medication Errors: Instruct patients to always check the insulin label before each injection to avoid medication errors. Humalog U-200 should not be transferred from the Humalog KwikPen to a syringe as overdose and severe hypoglycemia can occur.

Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50. If hypersensitivity reactions occur, discontinue the use of insulin and treat per standard of care until signs and symptoms resolve.

Hypokalemia: Hypokalemia may be life threatening. Insulins, including Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50, cause a shift in potassium from the extracellular to intracellular space possibly leading to hypokalemia, which, if untreated, may result in respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia (e.g., patients using potassium-lowering medications or medications sensitive to serum potassium concentrations).

Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists: Thiazolidinediones (TZDs), which are PPAR-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin, including Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50. This may lead to or exacerbate heart failure. Observe patients for signs and symptoms of heart failure and consider discontinuation or dose reduction of the PPAR-gamma agonist.

Hyperglycemia and Ketoacidosis Due to Insulin Pump Device Malfunction: Malfunction of the insulin pump device, infusion set, or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Patients using subcutaneous insulin infusion pumps must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure.

  • Adverse Reactions

Adverse reactions associated with Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50 include hypoglycemia, hypokalemia, allergic reactions, injection-site reactions, lipodystrophy, pruritus, rash, weight gain, and peripheral edema.

  • Drug Interactions

Some medications may alter glucose metabolism, insulin requirements, and the risk for hypoglycemia or hyperglycemia. Signs of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs. Particularly close monitoring may be required.

Please click to access Humalog  Full Prescribing Information, Humalog U-100  Patient Prescribing Information, Humalog U-200  Patient Prescribing Information, Humalog Mix75/25  Full Prescribing Information, Humalog Mix75/25  Patient Prescribing Information, Humalog Mix50/50  Full Prescribing Information, Humalog Mix50/50  Patient Prescribing Information, Insulin Lispro Injection Full Prescribing Information, and Insulin Lispro Injection  Patient Prescribing Information, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 Full Prescribing Information, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 Patient Prescribing Information, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 KwikPen Instructions for Use, Insulin Lispro Injection Junior KwikPen Instructions for Use.

Please click to access  Humalog U-100 KwikPen Instructions for Use, Humalog Junior KwikPen Instructions for Use, Humalog U-100 Vial Instructions for Use, Humalog Mix75/25 KwikPen Instructions for Use, Insulin Lispro Injection KwikPen Instructions for Use, and Insulin Lispro Injection Vial Instructions for Use included with your medication.

HI BOI SP U100 75/25 HCP ISI 10JAN2020

Humalog®, KwikPen®, Humalog® Junior KwikPen®, Humalog® Mix75/25TM, and Humalog® Mix50/50TM are trademarks and registered trademarks of Eli Lilly and Company, its subsidiaries, or affiliates, and are available by prescription only. 

Reference: 1. Data on file. Lilly USA, LLC; KwikPen Design Validation User Study. HUM20071024A.